Malcolm McColl is the founder of ImmVirX. ImmVirX has raised $47M in total funding. Latest round: Series B. Backed by One Ventures, Acorn Capital.
Malcolm McColl is the CEO and Co-Founder of ImmVirX, a clinical-stage biotech company focused on developing receptor-targeted oncolytic RNA immunotherapies for cancer. He brings experience from his previous work at Viralytics, which was acquired by Merck, and has a background in immunology.
Full founder directory · Investor directory · Company funding database · Fundraising library
The Startup Fundraising Platform
Raise funds for your startup
Find the right investors and get real replies — instantly, powered by AI.
Takes 30 seconds · No credit card · Cancel anytime
Slide-by-slide guide